Baxter and BioMerieux Collaborates to Develop Biomarkers for Acute Kidney Injury (AKI)

 Baxter and BioMerieux Collaborates to Develop Biomarkers for Acute Kidney Injury (AKI)

Baxter and BioMerieux Collaborates to Develop Biomarkers for Acute Kidney Injury (AKI)

Shots:

  • Baxter and BioMerieux enter into an agreement to develop biomarkers for identification & treatment for acute kidney injury (AKI)
  • The focus of the agreement is to utilize BioMerieux’s expertise in diagnostics & advancing Baxter’s critical care portfolio including nutrition, renal, hospital and surgical products
  •  Additionally, On April 24, 2018 BioMerieux has acquired Astute Medical to develop biomarkers, IGFBP-7, and TIMP-2 for the early risk assessment of acute kidney injuries

Click here to read full press release/ article | Ref: Baxter | Image: The Pharma Letter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post